<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82089">
  <stage>Registered</stage>
  <submitdate>14/06/2007</submitdate>
  <approvaldate>3/07/2007</approvaldate>
  <actrnumber>ACTRN12607000354482</actrnumber>
  <trial_identification>
    <studytitle>Adult stem cells and G-CSF in chronic ischaemic heart disease</studytitle>
    <scientifictitle>Granulocyte colony stimulating factor (G-CSF) in Angina patients with Ischaemic heart disease to stimulate Neovascularisation.</scientifictitle>
    <utrn />
    <trialacronym>GAIN II</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic ischaemic heart disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Granulocyte colony stimulating factor
Subcutaneous
Commenced at 4.5 mcg/kg/d
Three 5 day cycles (each cycle fortnight apart)</interventions>
    <comparator>Placebo 
Saline
Subcutaneous
Three 5 day cycles (each cycle fortnight apart)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of abnormal perfusion segments on adenosine cardiac magnetic resonance imaging</outcome>
      <timepoint>At 6 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.  Myocardial perfusion ratio index on MRI.</outcome>
      <timepoint>At 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.  Angina and quality of life measures (Seattle angina questionnaire)</outcome>
      <timepoint>At 3 months and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3.  Duke treadmill score</outcome>
      <timepoint>At 3 months and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Canadian class III/IV angina2. Angiographically proven coronary artery disease3. Demonstrable reversible ischaemia on adenosine stress cardiac MRI.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. MI &lt; 3 months2. Unstable angina3. Uncontrolled heart failure. 4. EF &lt; 20%5. Significant (&gt;50%) left main or left main equivalent disease6. Advanced coronary artery bypass graft disease.7. Factors preventing MRI including permanent pacemaker, implantable defibrillator, neurostimulator, severe claustrophobia8. Contraindications to adenosine including high degree heart block, severe bronchospasm.9. Proliferative retinopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be referred by their primary cardiologist. Once enrolled, subjects will be randomised to either G-CSF followed by placebo or Placebo followed by G-CSF therapy. This allocation will be concealed from both patient and the investigator responsible for patient enrolment and subsequent patient reviews. The allocation schedule will be held by Pharmacy.</concealment>
    <sequence>Simple randomisation by using a randomisation table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Subjects and the doctors in direct contact with subjects will be blinded.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>18/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>Australia wide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria St, Darlinghurst, Sydney 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>RT Hall Estate</fundingname>
      <fundingaddress>Nexia Court &amp; Company
Level 29 Australia Square
264 George St, Sydney</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>MBF</fundingname>
      <fundingaddress>50 Bridge Street,
Sydney NSW, 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Johnson Family Foundation</fundingname>
      <fundingaddress>Perpetual Foundation
GPO Box 4172, Sydney NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's Clinic Foundation</fundingname>
      <fundingaddress>Victoria St, Darlinghurst, Sydney</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Cardiovascular Lipid Research Grants (Pfizer Australia)</fundingname>
      <fundingaddress>PO Box 57, West Ryde</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>The Victor Chang Cardiac Research Institute</sponsorname>
      <sponsoraddress>384 Victoria St, Darlinghurst, Sydney</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Angina is a medical term used to describe pain (usually felt in the chest) due to coronary artery disease causing reduced blood flow to the heart. We are investigating the use of G-CSF to treat chronic angina in patients who have failed standard treatment with medications and or coronary stenting/coronary artery bypass surgery. G-CSF is a man made version of a naturally occuring hormone. There is experimental evidence that G-CSF can stimulate the formation of new blood vessels in the heart and protect heart muscle cells. Through these effects, we hypothesise that patients will derive improvements in blood flow to the heart and hence angina symptoms. We will be measuring the effects of G-CSF on blood flow to the heart with cardiac magnetic resonance imaging (MRI scan).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/06/2006</ethicapprovaldate>
      <hrec>H07/046</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sharon Chih</name>
      <address>The Victor Chang Cardiac Research Institute
384 Victoria St
Darlinghurst NSW 2010</address>
      <phone>+61 2 82958500</phone>
      <fax />
      <email>s.chih@victorchang.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sharon Chih</name>
      <address>The Victor Chang Cardiac Research Institute
384 Victoria St
Darlinghurst NSW 2010</address>
      <phone>+61 2 82958500</phone>
      <fax />
      <email>s.chih@victorchang.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>